In The News
Full Enrollment of Phase 1 Safety Trial Achieved of Intralytix Phage Product to Prevent Illness Caused by Shigella
03/24/2023
2 months ago
Intralytix, Inc. today announced successful, full enrollment of its Phase 1 clinical trial at the University of Maryland’s School of Medicine (UMSOM) in Baltimore under the direction of Dr. Wilbur Chen, Professor of Medicine and Chief of Adult Clinical Studies at UMSOM’s Center for Vaccine Development and Global Health (CVD).
Intralytix Receives USDA, NIFA Phase III SBIR Grant To Optimize Application of Its Salmonella-Targeting Bacteriophage Preparation SalmoFresh™ at Poultry and Meat Producers
03/09/2023
2 months ago
Intralytix, Inc., announced today that it has received a SBIR Phase III grant (Award No. 2023-70439-39191) from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA)'s Meat and Poultry Processing Research and Innovation Program, to optimize SalmoFresh™ application at small and medium poultry and meat producers.
Intralytix Launches Phase 1/2a Phage Therapy Trial to Prevent Illness Caused by Shigella
02/22/2023
3 months ago
Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of Intralytix phage therapy product ShigActive™ to prevent or reduce the severity of Shigella infections.
Intralytix receives Phase II Fast Track NIH SBIR contract to continue development of a universal, scale-independent AI-based platform for manufacturing high titer bacteriophage preparations for clinical applications.
08/22/2022
9 months ago
Intralytix, Inc. announced today that it has received a Phase II contract in the amount of $1,498,045. This contract is made through the Small Business Innovation Research (SBIR) program from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This project is the continuation of a successfully completed NIAID-funded Phase I contract.
Intralytix Granted Clearance by the FDA for an Investigational New Drug Application for Phase 1/2a Clinical Trials for Vancomycin Resistant Enterococci (VRE)-targeting Phage Preparation
05/09/2022
1 year ago
Intralytix, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product VRELysin™, a bacteriophage preparation to manage colonization of vancomycin resistant Enterococcus (VRE) in the human gut.
AB Agri has partnered with US biotechnology company Intralytix to explore the use of bacteriophages – the natural viruses of bacteria – in animal feed as an alternative to antibiotics and other drugs
11/30/2021
1 year ago
Both companies believe there is potential to use the abundant probiotic microorganisms to intensify natural processes, thereby tackling bacteria and boosting gut health without the need for broad spectrum antibiotic medication.
Intralytix Receives FDA Clearance for Investigational New Drug Application for Phase 1/2a Clinical Trials for Shigella-targeting Phage Preparation
10/25/2021
1 year ago
Intralytix, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product ShigActive™, a bacteriophage preparation to manage Shigella infections in humans.
Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology
10/07/2021
1 year ago
Intralytix, Inc. announced today that its food safety product, CampyShield™, has received GRAS (Generally Recognized as Safe) recognition from the Food and Drug Administration (FDA), GRAS No: GRN 000966.
Intralytix: Illuminating the Path to Safer Food Processing
09/07/2021
1 year ago
By harnessing the natural power of these bacteriophages, Intralytix offers robust food safety products designed to target some of the deadliest foodborne bacterial pathogens, including L. monocytogenes and E. coli.
Intralytix receives Fast Track NIH SBIR contract to develop a universal, scale-independent AI-based platform for manufacturing high titer bacteriophage preparations for clinical applications
08/16/2021
1 year ago
Intralytix, Inc. announced today that it has received a Phase I award in the amount of $299,672 with an option for a Phase II award in the amount of $1,498,045. This award is made through the Small Business Innovation Research (SBIR) program under a Fast-Track Phase I / Phase II program providing for up to $1.8 million from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Intralytix Receives SBIR Grant to Develop Phage Preparation for Reducing Vibrio parahaemolyticus Contamination of Foods
06/30/2021
1 year ago
Intralytix, Inc. announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Food and Agriculture (NIFA), an agency of the U.S. Department of Agriculture (USDA), for the development of a phage biocontrol solution for Vibrio parahaemolyticus in various food products, including seafood.
Intralytix awarded patent by USPTO for novel Shigella bacteriophages and their uses
07/14/2020
2 years ago
Intralytix, Inc. announced today that it has been issued a patent by the U.S. Patent & Trademark Office (USPTO) covering its Shigella bacteriophages and their various applications.
Intralytix enters into CRADA with the U.S. Army Combat Capabilities Development Command Soldier Center
06/08/2020
2 years ago
Intralytix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Soldier Center (CCDC SC) in Natick, Massachusetts. The CRADA will focus on developing a dehydration process for bacteriophage cocktails, for use as a non-chemical and environmentally friendly food safety intervention and mitigation strategy for bacterial pathogens in fresh military procured food items.
Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans
05/04/2020
3 years ago
Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella.
Intralytix Receives FDA Regulatory Clearance for Expanded Use in Red Meat for Phage-Based Salmonella Technology
11/19/2019
3 years ago
Intralytix, Inc. announced today that its food safety product, SalmoFresh™, has been granted a supplement to its GRAS (Generally Recognized As Safe) recognized status from the Food and Drug Administration (FDA), which expands the use of SalmoFresh™ to ready-to-eat and raw red meat carcasses, subprimals and trimmings.
Intralytix Receives FDA Regulatory Clearance and Expanded Use, Including in Ground Beef, for Phage-Based E. coli Food Safety Product
11/13/2019
3 years ago
Intralytix, Inc. announced today that its broader acting and expanded use food safety product, EcoShield PX™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA) for elimination of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli (STEC) in many foods, including ground beef.
Intralytix Enters Into Joint Collaboration Agreement with the Eliava Foundation and Ferring Pharmaceuticals
06/17/2019
3 years ago
Intralytix announces joint collaboration agreement to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine and Women's Health.
Intralytix Acquires Site for New Headquarters
05/11/2018
5 years ago
Intralytix, Inc. announced today that it has closed on the acquisition of a 33,000 sq. ft. building in Columbia, Maryland. The facility, located in the Columbia Gateway Community, will serve as the Company's new headquarters.
Intralytix Receives FDA clearance to initiate Phase I / IIa clinical trials
02/15/2018
5 years ago
Intralytix, Inc. announced today that it received clearance from the Food and Drug Administration (FDA) to initiate Phase I / IIa clinical trials at Mount Sinai hospital in New York, NY.
Lesaffre invests in Intralytix, a US biotechnology company
07/24/2017
5 years ago
Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize phage-based products.
Intralytix Receives FDA Regulatory Clearance for Phage-Based Shigella Technology
03/28/2017
6 years ago
Intralytix, Inc. announced today that its latest food safety product, ShigaShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).
Intralytix, Inc. and Ferring Pharmaceuticals partner to develop bacteriophage treatments
01/09/2017
6 years ago
Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.
Intralytix Receives USDA, NIFA Phase II SBIR Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogens Vibrio tubiashii and Vibrio coralliilyticus
03/08/2016
7 years ago
Intralytix, Inc., announced today that the company has received a SBIR Phase II grant from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA).
Intralytix and Ferring Pharmaceuticals Collaborate In Novel Bacteriophage-Based IBD Drug Development Project
07/13/2015
7 years ago
Intralytix, Inc., announced today that it has entered into a collaboration agreement with Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group headquartered in St. Prex, Switzerland.
Intralytix Receives Additional Regulatory Approval For ListShield™ - Phage-Based Food Safety Product Effective Against Listeria monocytogenes
01/05/2015
8 years ago
Intralytix, Inc. announced today that its food safety product, ListShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).
Intralytix Wins USDA Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogen, Vibrio tubiashii
07/13/2013
9 years ago
Intralytix, Inc. announced today that the company has received a SBIR Phase I grant from the U.S. Department of Agriculture (U.S.D.A.) to develop a bacteriophage (or phage) cocktail effective against the shellfish pathogen Vibrio tubiashii.
Intralytix Wins Regulatory Approval For Phage-Based Food Safety Product Effective Against Salmonella
02/27/2013
10 years ago
Intralytix, Inc. announced today that its latest food safety product, SalmoFresh™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).
Intralytix Signs Multiple Project Collaboration Agreement with Procter & Gamble
09/21/2011
11 years ago
Intralytix, Inc. announced today that it has entered into a Multiple Project Collaboration Agreement ("MPCA") with The Procter & Gamble Company (NYSE:PG).
Intralytix Awarded Grant For Managing Salmonella in Food
08/01/2011
11 years ago
Intralytix, Inc. announced today that it has been awarded a grant under a National Institute of Food And Agriculture (NIFA) / United States Department of Agriculture (USDA) Small Business Innovative Research (SBIR) Grants Program.
Intralytix Completes Regulatory Clearance for Phage-Based E. coli Food Safety Technology
06/14/2011
11 years ago
Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for EcoShield™.
Intralytix Receives Follow-On Army Contract To Develop A Phage-Based Probiotic To Manage Shigella Infections
04/11/2011
12 years ago
Intralytix, Inc. announced today that it has received a U.S. Army Phase II STTR contract supporting the further development of a bacteriophage-based probiotic preparation for managing Shigella infections.
03/22/2011
12 years ago
Food Safety News
March 22, 2011
Company Develops Natural Way to Fight E. coli
Intralytix's CSO Appointed Editor-In-Chief of New Phage Journal
02/09/2011
12 years ago
Intralytix, Inc. announced today that its Chief Scientific Officer, Dr. Alexander Sulakvelidze, has been appointed Editor-In-Chief of a new scientific journal called "Bacteriophage."
Intralytix Receives FDA Regulatory Clearance for Phage-Based E. coli Technology
02/08/2011
12 years ago
Intralytix, Inc. announced today that it has received regulatory clearance from the Food and Drug Administration for its phage-based EcoShield™ food safety product, effective against E. coli O157:H7.
Intralytix Wins Army Grant To Develop A Phage-Based Probiotic To
Manage Shigella Infections
10/07/2009
13 years ago
Intralytix, Inc.
announced today that it has received a U.S. Army Phase I STTR
grant supporting the development of a
bacteriophage-based probiotic preparation for managing
Shigella infections.
Intralytix Wins Army Grant To Develop A Phage-Based Probiotic To Manage Shigella Infections
10/07/2009
13 years ago
Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.
Intralytix Receives a Phase I U.S. Army grant supporting the development of a phage-based product for treating wounds infected with Acinetobacter baumannii.
09/11/2009
13 years ago
Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a phage-based product.
Intralytix Wins Army Grant for Salmonella and Shigella Technology
06/15/2009
13 years ago
Intralytix, Inc. announced today that it has been awarded a contract from the U.S. Army to develop a bacteriophage-based food safety product.
Intralytix Wins Army Grant to develop a bacteriophage-based food safety product for reducing or eliminating contamination from pathogenic Salmonella and Shigella spp.
06/15/2009
13 years ago
Intralytix, Inc. announced today that it has been awarded a contract from the U.S. Army to develop a bacteriophage-based food safety product for reducing or eliminating contamination from pathogenic
Intralytix awarded patent by USPTO for Bacteriophage treatment
of colonization by pathogen bacteria, including MRSA
12/09/2008
14 years ago
Intralytix,
Inc., announced today that it has been issued a patent by the
U.S. Patent & Trademark Office covering the use of
bacteriophages to reduce the risk of bacterial infection including MRSA.
Intralytix wins Phase III Army grant for E. Coli technology
11/26/2008
14 years ago
Intralytix, Inc., announced today that it has been named a recipient of a 2009 Army Commercialization Pilot Program (CPP) grant to support a phage-based technology development
04/04/2008
15 years ago
National Public
Radio -
April 4, 2008
Using 'Phage' Viruses to Help Fight Infection
NPR Talk of the Nation:Â Science Friday with Intralytix
Vice President, Alexander Sulakvelidze
Intralytix Wins Popular Science "Best of What's New" Award
for its food safety product ListShield™
11/13/2006
16 years ago
Intralytix, Inc., announced
today that it has won the Popular Science "Best of What's New"
award for its food safety product ListShield™.
FDA approves Intralytix's Food Safety Product (LMP 102)
08/19/2006
16 years ago
Intralytix, Inc.
announced today that the Food and Drug Administration has
approved LMP 102 for use on ready-to-eat food.
12/28/2004
18 years ago
CRC Press - December 28, 2004
Bacteriophages: Biology and Applications
528 page book provides a comprehensive overview of phage
history, biology, techniques, and applications
H.C. Wainwright & Co., LLC hosts the First Annual Bacteriophage Conference
11/30/2022
6 months ago
On November 30, 2022, H.C. Wainwright & Co., LLC hosted the First Annual Bacteriophage Conference to highlight what H.C. Wainwright & Co. believes to be a major pending inflection point in the field. Intralytix was one of the phage companies featured at the conference, with our President and CEO, Dr. Alexander "Sandro" Sulakvelidze presenting.
The State of Phage Therapy
03/02/2022
1 year ago
Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.
How bacteria-killing viruses are being used to keep food safe
01/12/2022
1 year ago
Bacteria-killing viruses, called bacteriophages, are increasingly being used to destroy harmful microbes
during food processing, to stop food rotting and to treat plant and animal diseases on farms.
Food Poisoning Sickens Millions a Year. Now, a Surprising Weapon Is Helping Protect Against Contamination
10/27/2021
1 year ago
Every year, one in seven people in America comes down with a foodborne illness, typically caused by a bacterial pathogen, including E.Coli, listeria, salmonella, or campylobacter
How bacteriophages can help us shape the microbiome
06/01/2021
2 years ago
An interview with Alexander "Sandro" Sulakvelidze, President and CEO of Intralytix, Inc.
Intralytix receives a positive #LuxTake by Lux Research
05/11/2021
2 years ago
Intralytix was given a "Positive" Lux Take by Lux Research in its report to its subscribing membership.
Antibiotic-resistant 'superbugs' could be the next big health threat. Beneficial viruses could be the solution
05/07/2021
2 years ago
Maryland is a hotspot for research and production of superbug-killing bacteriophages.
Phage Against the Machine
03/16/2021
2 years ago
If you thought food poisoning was just a matter of the occasional stomach upset from a dodgy shrimp or two, the CDC has some unsettling numbers for you.
Leading Bacteriophage Company Expands Clinical Pipeline, Poised for Growth in Maryland
06/16/2020
2 years ago
Intralytix, the largest food safety phage company in the world, sits on the precipice of substantial growth and success. 23 years of building unrivaled bacteriophage expertise, developing and securing 15 issued patents, and being one of two phage companies in the world with sales revenue have put this Columbia, Maryland-based company in a position to harness several positive macro-market forces to fuel its expansion.
UPDATE: EcoActive™ Bacteriophage Therapy Enters Clinical Trial at the Mount Sinai Hospital
02/08/2019
4 years ago
Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adhesive invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial.
Contest For The Best Cartoon Characters Of Bacteriophages
02/07/2019
4 years ago
Intralytix is holding a contest for the creation of cartoon characters depicting bacteriophages.
Intralytix, Inc. receives a U.S. Army award in support of studies on bacteriophages and the food microbiome.
11/29/2017
5 years ago
Intralytix, Inc. receives a U.S. Army award in support of studies on elucidating the interaction of bacteriophages with bacteria in various food matrixes and selected food safety interventions on the food microbiome.
Intralytix, Inc. enters into a collaboration agreement with the G. N. Gabrichevsky Research Institute for Epidemiology and Microbiology (GRIEM) (Moscow, Russia).
11/27/2017
5 years ago
Intralytix, Inc. announced that it has entered into a collaboration agreement for developing bacteriophage preparations against selected bacterial pathogens.
Interview with Intralytix's Dr. Alexander Sulakvelidze
09/17/2017
5 years ago
Bacteriophages: Nature's Answer to Killing Pathogens in Fresh Pet Food.
Intralytix was recently given a positive #LuxTake by Lux Research
06/28/2017
5 years ago
In the most recent report, Lux rated Intralytix as superior in 8 out of 10 categories used to rank the competitive companies.
Intralytix phage-based Shigella tech backed by FDA
04/18/2017
6 years ago
Intralytix Inc's product targeting Shigella has received GRAS (Generally Recognized As Safe) recognition from the US Food and Drug Administration (FDA).
11/28/2016
6 years ago
FDA on a Witch Hunt Against Commercial Pet Food? A Little Spritz of This Makes Pet Food Far Safer.
03/28/2016
7 years ago
Intralytix wins grant from the U.S. Department of Agriculture to develop a phage cocktail that will be effective against the pathogens that kill larval shellfish.
World Congress on Beneficial Microbes: Food, Pharma, Aqua & Beverages Industry
08/25/2015
7 years ago
Intralytix is exhibited at the World Congress on Beneficial Microbes in Valencia, Spain
Seafood Expo North America/Seafood Processing North America (SENA)
03/15/2015
8 years ago
Seafood Expo North America/Seafood Processing North America (SENA)
March 15-17, 2015
Intralytix at the SENA, Boston Convention & Exhibition Center, Boston, MA, USA
Intralytix Receives Additional Regulatory Clearance for SalmoFresh™
02/13/2015
8 years ago
Intralytix Receives Additional Regulatory Clearance for SalmoFresh™ - Phage-Based Food Safety Product Effective Against Salmonella.
Health Canada
12/12/2014
8 years ago
Health Canada
December 12, 2014
Health Canada approved the use of ListShield™ as a processing aid for ready-to-eat meat and poultry, smoked salmon, fresh-cut apples, and long leaf lettuce
10/31/2014
8 years ago
Health Canada
October 31, 2014
Health Canada approved the use of ListShield™ as a processing aid for ready-to-eat meat and poultry
10/16/2014
8 years ago
Health Canada
October 16, 2014
Health Canada approved the use of EcoShield™ as a processing aid for red meat
08/26/2014
8 years ago
Health Canada
August 26, 2014
Health Canada approved the use of SalmoFresh™ as a processing aid for various foods in Canada, in all jurisdictions recognized by Health Canada for the purposes of the iLONO policy
08/03/2014
8 years ago
National Food Service, Ministry of Health, Tel Aviv, Israel
August 3, 2014
Guidelines: Use of Bacteriophages (bacteria killing viruses) in Food (Ref: 70275202)
Baltimore Business Journal
05/01/2014
9 years ago
Baltimore Business Journal
May, 2014
Baltimore Business Journal recognized Intralytix as one of the top 25 biotechnology companies in 2014
03/20/2013
10 years ago
Food Safety News
March 20, 2013
New Spray Product Takes Aim at Salmonella on Poultry
02/01/2013
10 years ago
Environmental Health Perspectives
February 1, 2013
Phage Renaissance: New Hope against Antibiotic Resistance
09/28/2011
11 years ago
The Mark Steiner Show
September 28, 2011
Urbanite Radio Story: Healing Waters
08/29/2011
11 years ago
Urbanite
August 29, 2011
Healing Waters: In the Inner Harbor, the seeds of a medical breakthrough
12/03/2010
12 years ago
Journal of the American Veterinary Medical Association
December 3, 2010
Searching for self-replicating antimicrobials
09/27/2010
12 years ago
Los Angeles Times
September 27, 2010
In The Works:? New Ways to Fight Bacteria
10/16/2009
13 years ago
Gazette.Net Maryland Community Newspapers
October 16, 2009
BioWatch: Baltimore biotech turns to the past for cutting-edge
treatment
04/23/2007
16 years ago
New York News -
April 23, 2007
Spray to quell E. coli
Baltimore company seeking FDA approval for viral substance
to kill the bacteria on produce, raw meat
10/09/2006
16 years ago
CBS News Video
Spray For Bacteria-Free Meat
Scientists in Baltimore, Maryland are harnessing billions of
microscopic organisms in a war against bacteria such as E. coli,
listeria and salmonella
09/19/2006
16 years ago
CNN Video -
September 19, 2006
Dr. Sanjay Gupta on the recent FDA approval of ListShield
U.S. OKs spray to kill food bacteria
Baltimore firm wins FDA nod for mix of beneficial viruses
08/19/2006
16 years ago
PRESS RELEASE - August 19,
2006
FDA approves Intralytix's Food Safety Product (LMP 102)
02/01/2006
17 years ago
Seed Magazine -
Feb/Mar, 2006
Trail Phage
Why antibiotics are so 1990's and how their complement may be
squelched by the FDA
Voice of America
10/27/2003
19 years ago
"Our World" Broadcast featuring Intralytix
In the never-ending battle against bacterial infection
Wired Magazine
10/27/2003
19 years ago
Voice of America - VOA
News.com, October 27, 2003
"Our World" Broadcast featuring Intralytix
In the never-ending battle against bacterial infection,
antibiotics have been the main line of de
03/31/2003
20 years ago
LA Times, March 31, 2003
Enlisting viruses to battle bacteria
As even the most potent antibiotics lose the upper hand against
bacteria, researchers are again exploring the potential of
bacteriophage .
10/25/2002
20 years ago
Bacteriophage therapy, pioneered in Stalin-era Russia, is attracting renewed attention in the West as a potential weapon against drug-resistant bugs and hard-to-treat infections
09/20/2002
20 years ago
CBS News - 48 Hours, September
20, 2002
Silent Killers: Fantastic Phages?
(CBS) After breaking his foot five years ago, Toronto bass
player Alfred Gertler got an infection that antibiotics couldn't cure
01/07/2002
21 years ago
Washington Techway, January 7, 2002
"Beating Superbugs"
After years of research, phage therapy inches closer to market
12/01/2001
21 years ago
Newsweek International,
December, 2001
"Superbug Killers"
Western scientists discovered a potent
weapon against antibiotic-resistant bacteria in an unlikely place . . .
12/01/2001
21 years ago
US News & World Report,
December, 2001
"Infectious Arms Race"
Forging new weapons against resurgent bacterial killers
FoodTech Source
09/01/2001
21 years ago
FoodTech Source, September,
2001
"Phage-Enhanced Food Safety"
Agricultural Research
Magazine
07/01/2001
21 years ago
Agricultural Research
Magazine, July, 2001
"Turning the Phage on Produce Pathogens"
Tiny viruses, called phages, infect and
kill bacteria naturally . . .
Smithsonian Magazine
10/01/2000
22 years ago
Smithsonian Magazine,
October, 2000
"The Return of the Phage"
As deadly bacteria increasingly resist antibiotics, researchers
try to improve a World War I era weapon . . .
Science Service, Inc.
06/03/2000
23 years ago
Science Service, Inc., June
3, 2000
"Viruses That Slay
Bacteria Draw New Interest"
McMahonMed
06/01/2000
23 years ago
McMahonMed,
June 20, 2000
"Viruses Called Bacteriophages Resurface As Viable Option
To Fight Infections"
See
entire story
Washington Techway
03/13/2000
23 years ago
Washington Techway, March 13, 2000 "Planning
for the day antibiotics fail" (Intralytix
Inc's bacteriophage research plans)
New York Times
02/06/2000
23 years ago
New York Times, February 6, 2000
"A Stalinist Antibiotic Alternative"
DoubleTwist
01/21/2000
23 years ago
DoubleTwist, January 21, 2000
"The return of bacteriophage therapies"